{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:03:16Z","timestamp":1783612996151,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Niraparib is approved for maintenance treatment of tubo-ovarian cancer patients, but data on older patients are limited. This retrospective study evaluated its safety and efficacy in primary advanced tubo-ovarian cancer, focusing on patients\u2009\u2265\u200975\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Women aged\u2009\u2265\u200950\u00a0years diagnosed with primary high-grade serous tubo-ovarian cancer, treated with niraparib between 2019\u20132023, were enrolled. Patients were stratified into three groups: A (50\u201364\u00a0years), B (65\u201374\u00a0years), and C (\u2265\u200975\u00a0years). The primary outcome was progression-free survival. The secondary outcomes were toxicity and dose reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      127 patients were identified: 62 (48.8%) group A, 26 (20.5%) group B, and 39 (30.7%) group C. Baseline characteristics were comparable across groups, excluding a higher proportion of interval cytoreductive surgeries (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), residual tumor (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) and Eastern Cooperative Oncology Group (ECOG)\u2009&gt;\u20091 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) in group C. Most patients started niraparib at 200\u00a0mg\/day with dose reductions primarily occurred within fourth cycle. Dose reductions were observed in 77.4%, 69.2% and 56.4% of patients in groups A, B, and C, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.08). In patients\u2009\u2265\u200975\u00a0years, 26 (66.7%) discontinued treatment due to disease progression (48.7%) or toxicity (17.9%). There were no significant differences in common or grade\u2009\u2265\u20093 adverse events between groups. Progression-free survival was 12\u00a0months (95%CI: 2.0\u201325.0) for group A, 29\u00a0months (95%CI: 11.0\u201352.0) for group B, and 16\u00a0months (95%CI: 1.0\u201331.0) for group C (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.78).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that niraparib is safe and well-tolerated in aged\u2009\u2265\u200975\u00a0years. Concerns about toxicity should not preclude the enrollment of elderly patients in treatment regiments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-025-02914-y","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:55:31Z","timestamp":1762268131000},"page":"2652-2661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4614-9261","authenticated-orcid":false,"given":"Adriana Ionelia","family":"Apostol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4372-4220","authenticated-orcid":false,"given":"Matteo","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1702-5859","authenticated-orcid":false,"given":"Carolina Maria","family":"Sassu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4677-469X","authenticated-orcid":false,"given":"Serena Maria","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-3888","authenticated-orcid":false,"given":"Laura","family":"Vertechy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1233-9850","authenticated-orcid":false,"given":"Giorgia","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-832X","authenticated-orcid":false,"given":"Ilary","family":"Ruscito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-4193","authenticated-orcid":false,"given":"Filippo Maria","family":"Capomacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-9041","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-8956","authenticated-orcid":false,"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2914_CR1","unstructured":"NCI. SEER Stat Fact Sheets: Ovary Cancer. Surveillance, Epidemiology, and End Results Program, 1975-2012. SEER"},{"issue":"25","key":"2914_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381(25):2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"issue":"26","key":"2914_CR3","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"issue":"25","key":"2914_CR4","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"issue":"34","key":"2914_CR5","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","volume":"40","author":"BJ Monk","year":"2022","unstructured":"Monk BJ, Parkinson C, Lim MC et al (2022) A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ ENGOT-ov45). J Clin Oncol 40(34):3952\u20133964. https:\/\/doi.org\/10.1200\/JCO.22.01003","journal-title":"J Clin Oncol"},{"issue":"7","key":"2914_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1273::AID-CNCR13>3.0.CO;2-4","volume":"80","author":"R Yancik","year":"1997","unstructured":"Yancik R (1997) Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 80(7):1273\u20131283","journal-title":"Cancer"},{"key":"2914_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.critrevonc.2018.08.008","volume":"131","author":"J Feliu","year":"2018","unstructured":"Feliu J, Heredia-Soto V, Giron\u00e9s R et al (2018) Can we avoid the toxicity of chemotherapy in elderly cancer patients? Crit Rev Oncol Hematol 131:16\u201323. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.08.008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2914_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ygyno.2018.12.009","volume":"152","author":"M Fabbro","year":"2019","unstructured":"Fabbro M, Moore KN, D\u00f8rum A et al (2019) Efficacy and safety of niraparib as maintenance treatment in older patients (\u2265 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16\/NOVA trial. Gynecol Oncol 152(3):560\u2013567. https:\/\/doi.org\/10.1016\/j.ygyno.2018.12.009","journal-title":"Gynecol Oncol"},{"issue":"22","key":"2914_CR9","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375(22):2154\u20132164. https:\/\/doi.org\/10.1056\/NEJMoa1611310","journal-title":"N Engl J Med"},{"issue":"8","key":"2914_CR10","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdy255","volume":"29","author":"JS Berek","year":"2018","unstructured":"Berek JS, Matulonis UA, Peen U et al (2018) Safety and dose modification for patients receiving niraparib. Ann Oncol 29(8):1784\u20131792. https:\/\/doi.org\/10.1093\/annonc\/mdy255","journal-title":"Ann Oncol"},{"key":"2914_CR11","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute"},{"issue":"19","key":"2914_CR12","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Fleming GF, Brady MF et al (2019) Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 381(19):2403\u20132415. https:\/\/doi.org\/10.1056\/NEJMoa1909707","journal-title":"N Engl J Med"},{"issue":"11","key":"2914_CR13","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/ijgc-2022-003614","volume":"32","author":"BA Maiorano","year":"2022","unstructured":"Maiorano BA, Maiorano MFP, Lorusso D et al (2022) Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 32(11):1410\u20131418. https:\/\/doi.org\/10.1136\/ijgc-2022-003614","journal-title":"Int J Gynecol Cancer"},{"key":"2914_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ygyno.2024.03.009","volume":"187","author":"G Valabrega","year":"2024","unstructured":"Valabrega G, Pothuri B, Oaknin A et al (2024) Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Gynecol Oncol 187:128\u2013138. https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2914_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1525-1438.2007.00836.x","volume":"17","author":"T Susini","year":"2007","unstructured":"Susini T, Amunni G, Busi E et al (2007) Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients. Int J Gynecol Cancer 17(3):581\u2013588. https:\/\/doi.org\/10.1111\/j.1525-1438.2007.00836.x","journal-title":"Int J Gynecol Cancer"},{"key":"2914_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051451","author":"Y Joueidi","year":"2020","unstructured":"Joueidi Y, Dion L, Bendifallah S et al (2020) Management and survival of elderly and very elderly patients with ovarian cancer: an age-stratified study of 1123 women from the FRANCOGYN group. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9051451","journal-title":"J Clin Med"},{"issue":"3","key":"2914_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ygyno.2017.03.016","volume":"145","author":"JL Warren","year":"2017","unstructured":"Warren JL, Harlan LC, Trimble EL et al (2017) Trends in the receipt of guideline care and survival for women with ovarian cancer: a population-based study. Gynecol Oncol 145(3):486\u2013492. https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2914_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1006\/gyno.1998.5337","volume":"73","author":"NG Cloven","year":"1999","unstructured":"Cloven NG, Manetta A, Berman ML et al (1999) Management of ovarian cancer in patients older than 80 years of age. Gynecol Oncol 73(1):137\u2013139. https:\/\/doi.org\/10.1006\/gyno.1998.5337","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2914_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ygyno.2005.04.037","volume":"98","author":"D Uyar","year":"2005","unstructured":"Uyar D, Frasure HE, Markman M et al (2005) Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol 98(3):403\u2013408. https:\/\/doi.org\/10.1016\/j.ygyno.2005.04.037","journal-title":"Gynecol Oncol"},{"issue":"10","key":"2914_CR20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18757","volume":"13","author":"M Tucker","year":"2021","unstructured":"Tucker M, Padarti A (2021) Thrombocytopenia due to direct oral anticoagulation and low-molecular-weight heparin. Cureus 13(10):e18757. https:\/\/doi.org\/10.7759\/cureus.18757","journal-title":"Cureus"},{"issue":"18","key":"2914_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood.2022017634","volume":"143","author":"P Foy","year":"2024","unstructured":"Foy P, Friedman KD, Michaelis LC (2024) How I diagnose and treat thrombocytopenia in geriatric patients. Blood 143(18):214\u2013223. https:\/\/doi.org\/10.1182\/blood.2022017634","journal-title":"Blood"},{"issue":"5\u20136","key":"2914_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/10245330400010620","volume":"9","author":"S Aref","year":"2004","unstructured":"Aref S, Mabed M, Selim T et al (2004) Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia. Hematology 9(5\u20136):351\u2013356. https:\/\/doi.org\/10.1080\/10245330400010620","journal-title":"Hematology"},{"key":"2914_CR23","unstructured":"Balducci L (2007) Cancer-related anemia: special considerations in the elderly. Oncology (Williston Park). 21(1):81\u20136, 90 (discussion 90, 100, 104)"},{"key":"2914_CR24","doi-asserted-by":"publisher","unstructured":"Cullimore V., Gaitskell K., Newhouse R., et al (2025) Advanced epithelial ovarian cancer in elderly patients. IJGC. https:\/\/doi.org\/10.1016\/j.ijgc.2025.102017","DOI":"10.1016\/j.ijgc.2025.102017"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02914-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02914-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02914-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:02:42Z","timestamp":1764021762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02914-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2914"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02914-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CM is on the consultant\/advisory board for Clovis, Pharmamar, GSK, AstraZeneca and MSD, and received travel accommodation from Pharmamar and Roche. AF reports commercial interests with AstraZeneca, MSD, Johnson & Johnson and Pharmamar. GS reported research support from MSD and honoraria from Clovis Oncology, and he was a consultant for GSK, Tesaro and Johnson & Johnson. SMB is on the consultant\/advisory board for GSK, AstraZeneca and Pharmamar. All the other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study involves human participants and was approved by Comitato Etico Territoriale Lazio Area 3, Fondazione Policlinico A. Gemelli (IRCCS ID: 6356). Participants gave informed consent to participate in the study before taking part.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}